NCT05358938Active, not recruitingEarly phase 1
Exercise to Boost Response to Checkpoint Blockade Immunotherapy
Source: ClinicalTrials.gov · Last updated 15 Sept 2026
Brief summary (registry, in English)
30 minutes of moderate exercise on an arm ergometer, a cycle ergometer, or a treadmill prior to each administration of standard of care checkpoint blockade immunotherapy across all cycles
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Early phase 1
- Study type
- Interventional
- Enrollment
- 22 (actual)
- First submitted
- 28 Apr 2022
- Start date
- 21 Jun 2022
- Primary completion date
- 6 Oct 2024
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Diseases
- Melanoma
- NCT number
- NCT05358938
What you commit to
- Study type: Interventional · Early phase 1
- Participants enrolled: 22
- From 21 Jun 2022 to the primary completion date, 6 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Presence of medical conditions, such as severe cardiovascular disease for which an exercise intervention may not be warranted.
Other
- Presence of major postoperative complications for which an exercise intervention may not be warranted.
Criteria the registry did not label
- Inclusion Criteria:
- Age ≥ 18 years
- Able to read and speak English fluently
- Capable of giving informed consent
- Reported ability to complete 20-30 minutes moderate exercise per positive response to "can you currently walk unaided for six minutes or more?".
- Scheduled for first-time checkpoint blockade immunotherapy with FDA-approved drugs, including avelumab, cemiplimab, ipilimumab, nivolumab, pembrolizumab or relatlimab in the absence of other therapies (e.g. targeted therapy)
- Melanoma patients (adjuvant setting)
- Melanoma patients (neoadjuvant setting)
- cuSCC patients (neoadjuvant setting)
- Merkel cell carcinoma patients (neoadjuvant setting)
- Participants may also be required to have a full COVID vaccination series; the most up-to-date best practice guidelines for research at Moffitt Cancer Center will dictate the need for such a vaccination series.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Moffitt Cancer Center Coordinator of this site? Confirm its status | Tampa | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.